Header ImmunOs

The raise underlines our promising, first-in-class immunotherapy approach for the treatment of both solid and liquid tumors. The funding allows us to advance our lead program, IOS-1002, into clinical trials, expand our pipeline in oncology and autoimmune disease, and strengthen our transatlantic operations.

Sean R. Smith - CEO


Founded in 2014 as a spin off from the Universities of Zurich and Basel, ImmunOs Therapeutics is a preclinical stage biotech company which develops a proprietary target discovery platform allowing to discover novel molecules inspired by HLA molecules and physiological immunosuppressive molecules. The company is located in Schlieren (Zurich, Switzerland) with subsidiaries in the US and Australia.

ImmunOs raised a CHF 71M (USD 74M) Series B financing in June 2022 co-led by Gimv, Samsara Biocapital and Lightspeed Venture Partners, with significant participation from Mission Biocapital, GL Capital, Peak6 Strategic Capital, and Fiscus Financial, as well as existing investors Pfizer Ventures, BioMed Partners, and Schroder Adveq. The proceeds of the Series B will be used to fund the clinical development of ImmunOs’ lead program, IOS-1002, through Phase 2 clinical trials and to progress additional oncology and autoimmune disease programs. IOS-1002 will enter a Phase 1 clinical trial in the second half of 2022.

Icon entry


Icon employees

15 FTE

Icon location


When ambition meets ambition

ImmunOs’ approach of identifying HLA molecules with naturally optimized affinity and specificity profiles is not just elegant but also truly differentiated – a novel modality leveraging the co-evolution of immune-regulatory mechanisms. Despite all advances in therapies, cancer remains one of the major medical challenges and ImmunOs’ molecules activating both the innate as well as the adaptive immune system promise a paradigm shift in how we can turn the patients’ own immune system against malignancies.

Together, we build a leading company

ImmunOs’ vision of leveraging natural HLA biology to address major unmet needs in patients fully embodies the mission of Gimv´s Life Sciences platform: Building leading companies that have a lasting impact on patients and society. Next to exciting science, we also invest in a relentlessly committed team that wants to bring groundbreaking science into the clinic and we are more than proud to support the team on this journey.


Immuno-oncology for hematological and solid tumors